 Cancer Research UK | Analysis reveals most common Cancer Drugs Fund applications Cancer Research UK Other drugs that received a high number of applications under the Cancer Drugs Fund included lapatinib (Tyverb), rituximab (MabThera) and everolimus (Afinitor). Professor Adrian Newland, chair of London New Cancer Drugs Group welcomed the analysis. |
